Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Portuguese
  • Polish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Gut microbiota key to variability in statin response
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Gut microbiota key to variability in statin response
Gastroenterology

Gut microbiota key to variability in statin response

Drug interaction
Gastroenterology

Today, 25%-30% of people over the age of 40-50 in Europe and the United States take statins. However, variability between patients in their response to treatment remains a challenge for clinicians. Can the characteristics of patients’ gut microbiota help us predict and manage this variability?

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail
Le microbiote intestinal, clé de la variabilité de la réponse aux statines

About this article

Created 19 September 2022
Updated 24 July 2024

Statins reduce the risk of atherosclerotic cardiovascular disease by inhibiting the activity of the 3-hydroxy-3-methylglutarate-coenzyme-A (HMG-CoA) reductase enzyme involved in the hepatic synthesis of low-density lipoprotein (LDL). Unfortunately, their effectiveness on LDL levels varies considerably among patients and adverse effects can occur, particularly insulin resistance, which increases the risk of type 2 diabetes mellitus. For physicians, determining the “maximum tolerated dose” for each patient based on the guidelines1 is often down to trial and error. However, this approach wastes time and can undermine patient compliance.

A blood marker to measure response to statins

Recent studies have already shown links between the gut microbiota and atherosclerotic cardiovascular risk, but also between the microbiota and statin use. Now US researchers2 have studied the gut flora’s role in responses to statins. By metabolizing statins, bacteria in the gut microbiota may modulate their bioavailability and potency to the host, or even contribute to their adverse effects. In a US cohort of 1,848 adults, 244 of whom were statin users, the researchers first validated a marker of statin response, plasma levels of the HMG-CoA reductase substrate, or HMG. HMG levels were found to be significantly higher in statin users than in non-users, and were negatively correlated with blood LDL levels in statin users only. The level of HMG reflected both the intensity of statin therapy and the presence of genetic variants in patients affecting their response to therapy.

Microbiota profile influences treatment efficacy and metabolic risk

The researchers then studied the association between statin efficacy as measured by HMG levels, the effect of statins on glucose control as measured by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) score, and the composition of the gut microbiota, analyzed via 16S rRNA sequencing. They found that a more Bacteroides-enriched and diversity-depleted gut microbiome was associated with more intense statin responses, both in terms of efficacy and adverse effects on glucose control. However, a flora richer in Ruminococcaceae seemed to protect against the metabolic risk. These results were confirmed in a European cohort of 991 subjects whose gut microbiota was sequenced using a different method.

 

Towards precision statin therapies? 

 

This work not only explains variability in statin response, but also holds out the prospect of clinical tools to manage this variability. Indeed, plasma levels of HMG may supplement LDL levels as a source of information on treatment efficacy. Identifying the gut microbiota profile of patients may also allow us to predict responses to statins, to improve such responses using probiotics where necessary, and lastly, to propose to patients a more personalized treatment strategy for cardiovascular diseases.

Sources

1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255]. Eur Heart J. 2020;41(1):111-188

2. Wilmanski T, Kornilov SA, Diener C, et al. Heterogeneity in statin responses explained by variation in the human gut microbiome. Med (New York, N.Y.). 2022 Jun;3(6):388-405.e6

Tags
Statins Type 2 diabetes Insulin Drug interaction Metabolism Microbiome Flora

    See also

    Can statins combat intestinal dysbiosis?
    When the bacteria in the intestinal microbiota store medicines
    Created 19 September 2022
    Updated 24 July 2024

    About this article

    To know more about this topic.

    Main topic

    Drug interaction

    Medical practice

    Gastroenterology

    Content type

    News
    Gastroenterology

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial...

    Find out more

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irrita...

    Find out more

    Probiotics: what exactly are we talking about?

    From the Latin pro and Greek bios meaning “for life”, the term “probiotic” was suggested over 60 year...

    Find out more

    How do you choose a probiotic for your patient?

    Faced with a plethora of products on the market, it's not always easy for health professionals to sug...

    Find out more

    The Janus face of Antibiotics: Life Savers and Microbiota Disruptors

    A page turns: with the advent of antibiotics in the...

    Find out more

    Fecal transplantation - ready for prime time?

    Congress review By Pr. Danny De Looze Department of Gastroenterology University Hospital Gent, Belgi...

    Find out more

    Focus on antibiotic associated diarrhea (AAD)

    Find out more

    Dampening gastrointestinal inflammation through nutrition

    by Dr Genelle Healey

    Find out more

    Continue reading

    News
    Actu PRO : Malnutrition : agir sur le microbiote pour améliorer la croissance, un prototype à l’essai
    08.07.2021

    Malnutrition: acting on the microbiota in order to improve growth, a trial prototype

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article
    Actu PRO : Alcoolisme : expliquer les troubles sociaux grâce au microbiote
    27.01.2021

    Alcoholism: explaining social disorders thanks to the microbiota

    Read the article
    20.03.2025

    Entacapone and the gut: a hidden impact on parkinson’s care

    Read the article
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Portuguese
    • Polish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo